Serum Biglycan as a Diagnostic Marker for Non-Alcoholic Steatohepatitis and Liver Fibrosis


Cengiz M., Yilmaz G., ÖZENİRLER MAYER S.

CLINICAL LABORATORY, vol.67, no.3, pp.804-820, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 67 Issue: 3
  • Publication Date: 2021
  • Doi Number: 10.7754/clin.lab.2020.200709
  • Journal Name: CLINICAL LABORATORY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
  • Page Numbers: pp.804-820
  • Keywords: biglycan, liver fibrosis, NAFLD, NASH, non-invasive marker, MEAN PLATELET VOLUME, IDIOPATHIC THROMBOCYTOPENIC PURPURA, SIZE DEVIATION WIDTH, PREDICTORS, CHILDREN
  • Gazi University Affiliated: Yes

Abstract

Background: Non-alcoholic steatohepatitis (NASH) has risen in prevalence substantially through the years. Although course and progression of the disease are variable, fibrosis is the most important factor. We intended to explore utility of serum biglycan (BGN) in NASH and its capacity in anticipating liver fibrosis.